Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bitauto (BITA) downgraded to Underweight at Morgan Stanley by analyst Amanda Chen, who cited the slowdown in the ad and subscription business, aggressive transaction monetization that could result in dealer push back, and less transparent disclosures. 2. Genesis Healthcare (GEN) downgraded to Underperform at BofA/Merrill citing reduced guidance, industry wide pressures and low debt coverage. 3. Bank of America (BAC) downgraded to Market Perform at Keefe Bruyette by analyst Brian Kleinhanzl, who said the bank has more work to do to improve returns and drive shareholder value higher longer term. 4. UBS (UBS )double downgraded to Underperform at Keefe Bruyette with a price target of CHF 16. 5. Deutsche Bank (DB) downgraded to Sell at Berenberg citing leverage concerns. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

RBC Capital analyst Anke Reingen lowered the firm's price target on UBS to CHF 28 from CHF 29 and keeps an Outperform rating on the shares. The analyst feels that concerns over the TBTF proposal are "justified" and wanted to see more visibility, which "should remove the overhang to focus on the longer-term attraction of the UBS investment case."

As previously reported, Citi analyst Andrew Coombs downgraded UBS to Neutral from Buy with a CHF 27 price target. Following the "sharp rally" in shares, which are up 42% over the past year, the firm contends that "one really has to now look out beyond 2206 to try to justify the current multiple." Swiss authorities' new capital proposals add greater uncertainty on capital return, while the current multiple "now gives little buffer for execution risk" related to the integration of Credit Suisse, the analyst added.

Morgan Stanley lowered the firm's price target on UBS to CHF 31 from CHF 33 and keeps an Overweight rating on the shares.